IMGN
ImmunoGen, Inc.
16.14
USD
This page is just a preview of the data found in TrendSpider’s full version
ImmunoGen, Inc. stock is up 14.96% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 58.82% of the previous 33 November’s closed higher than October. In the last 10 Unusual Options Trades, there were 8 CALLs, 2 PUTs. 67% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 17 Nov 16:13 | 17 Nov, 2023 | 14.00 | 2691 | ||
| 17 Nov 17:29 | 16 Jan, 2026 | 17.00 | 150 | ||
| 17 Nov 17:29 | 16 Jan, 2026 | 17.00 | 150 | ||
| 17 Nov 17:43 | 17 Jan, 2025 | 20.00 | 315 | ||
| 17 Nov 17:47 | 17 Jan, 2025 | 17.00 | 440 | ||
| 20 Nov 14:55 | 19 Dec, 2025 | 15.00 | 76 | ||
| 20 Nov 14:59 | 19 Jan, 2024 | 21.00 | 1127 | ||
| 20 Nov 16:41 | 19 Jan, 2024 | 17.00 | 2043 | ||
| 20 Nov 18:42 | 19 Jan, 2024 | 15.00 | 7156 | ||
| 21 Nov 19:29 | 19 Jan, 2024 | 16.00 | 820 |
ImmunoGen, Inc. develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer.
